New Delhi - India's largest generics drug maker Ranbaxy Laboratories reported flat earnings in the June quarter despite strong sales.


The company's consolidated net profit in Q2 of 2008 stood at Rs.160.80 crore, up from Rs.160.40 crore posted in Q2 of 2007 (year-on-year or YoY rise of 0.24 percent).
During the same period, the company's sales rose from Rs.1623.80 crore to Rs.1829.60 crore (YoY rise of 12.67 percent).
The company, however, said the figures do not include foreign exchange loss and gains. Taking foreign exchange loss into consideration, the reported net profit stood at Rs.22.90 crore, hurt by a foreign-exchange loss of Rs.193 crore as against a net profit of Rs.266 crore in Q2 of 2007, which included a foreign-exchange gain of Rs.201 crore.
Regionwise, Ranbaxy saw its sales surge 18 percent, 3 percent, 4 percent, 20 percent and 11 percent in North America, India, Europe, Asia Pacific & CIS (excluding India), and Rest of the World respectively.
Emerging markets contributed 53 percent of global sales and grew 9 percent. Key countries in Latin America, Asia Pacific and Africa contributed to the growth in emerging markets, the company said.

Don't expect the expected from Dibakar Banerjee.
There is no proposal for government-run State Bank of India to take over any oth...

